Logo image of DRTS

ALPHA TAU MEDICAL LTD (DRTS) Stock Fundamental Analysis

NASDAQ:DRTS - Nasdaq - IL0011839383 - Common Stock - Currency: USD

2.765  -0.04 (-1.6%)

Fundamental Rating

2

DRTS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of DRTS is average, but there are quite some concerns on its profitability. DRTS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DRTS has reported negative net income.
In the past year DRTS has reported a negative cash flow from operations.
DRTS had negative earnings in each of the past 5 years.
In the past 5 years DRTS always reported negative operating cash flow.
DRTS Yearly Net Income VS EBIT VS OCF VS FCFDRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -28.76%, DRTS is in line with its industry, outperforming 44.21% of the companies in the same industry.
Looking at the Return On Equity, with a value of -37.32%, DRTS is in line with its industry, outperforming 55.79% of the companies in the same industry.
Industry RankSector Rank
ROA -28.76%
ROE -37.32%
ROIC N/A
ROA(3y)-39.96%
ROA(5y)-32.62%
ROE(3y)-69.5%
ROE(5y)-52.3%
ROIC(3y)N/A
ROIC(5y)N/A
DRTS Yearly ROA, ROE, ROICDRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DRTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRTS Yearly Profit, Operating, Gross MarginsDRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, DRTS has more shares outstanding
Compared to 1 year ago, DRTS has a worse debt to assets ratio.
DRTS Yearly Shares OutstandingDRTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
DRTS Yearly Total Debt VS Total AssetsDRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

DRTS has an Altman-Z score of 2.98. This is not the best score and indicates that DRTS is in the grey zone with still only limited risk for bankruptcy at the moment.
DRTS has a Altman-Z score of 2.98. This is in the better half of the industry: DRTS outperforms 67.89% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that DRTS is not too dependend on debt financing.
DRTS has a better Debt to Equity ratio (0.07) than 63.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 2.98
ROIC/WACCN/A
WACCN/A
DRTS Yearly LT Debt VS Equity VS FCFDRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

DRTS has a Current Ratio of 11.66. This indicates that DRTS is financially healthy and has no problem in meeting its short term obligations.
DRTS has a Current ratio of 11.66. This is amongst the best in the industry. DRTS outperforms 94.74% of its industry peers.
DRTS has a Quick Ratio of 11.66. This indicates that DRTS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.66, DRTS belongs to the top of the industry, outperforming 95.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.66
Quick Ratio 11.66
DRTS Yearly Current Assets VS Current LiabilitesDRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

DRTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.44%.
EPS 1Y (TTM)-19.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.97% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.07%
EPS Next 2Y-6.5%
EPS Next 3Y15.11%
EPS Next 5Y19.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRTS Price Earnings VS Forward Price EarningsDRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRTS Per share dataDRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

DRTS's earnings are expected to grow with 15.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.5%
EPS Next 3Y15.11%

More info and screens

0

5. Dividend

5.1 Amount

DRTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA TAU MEDICAL LTD

NASDAQ:DRTS (3/7/2025, 8:20:20 PM)

2.765

-0.04 (-1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)N/A N/A
Inst Owners1.89%
Inst Owner Change-0.14%
Ins Owners25.56%
Ins Owner ChangeN/A
Market Cap193.83M
Analysts86
Price Target8.93 (222.97%)
Short Float %0.14%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.15%
Min EPS beat(2)13.73%
Max EPS beat(2)14.58%
EPS beat(4)4
Avg EPS beat(4)19.88%
Min EPS beat(4)8.41%
Max EPS beat(4)42.81%
EPS beat(8)7
Avg EPS beat(8)25.47%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB 2.62
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.76%
ROE -37.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.96%
ROA(5y)-32.62%
ROE(3y)-69.5%
ROE(5y)-52.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 527.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.66
Quick Ratio 11.66
Altman-Z 2.98
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)354.49%
Cap/Depr(5y)1419.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
EPS Next Y-8.07%
EPS Next 2Y-6.5%
EPS Next 3Y15.11%
EPS Next 5Y19.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.83%
EBIT Next 3Y14.11%
EBIT Next 5YN/A
FCF growth 1Y-10.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.27%
OCF growth 3YN/A
OCF growth 5YN/A